ReviewFrontiers in pharmacology2015
Complementary and synergistic therapeutic effects of compounds found in Kampo medicine: analysis of daikenchuto.
Review in Frontiers in pharmacology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed, 2 syntheses or guidelines pooled it, 81 citations in OpenAlex.
- Efficacy of daikenchuto, a traditional Japanese Kampo medicine, for postoperative intestinal dysfunction in patients with gastrointestinal cancers: meta-analysis.International journal of clinical oncology · 2019Pooled it
- Daikenchuto for reducing postoperative ileus in patients undergoing elective abdominal surgery.The Cochrane database of systematic reviews · 2018Pooled it
- Evaluation of TU-100 (Daikenchuto), a Traditional Japanese Kampo Medicine, as an Adjunct to Enhanced Recovery After Surgery, for Acceleration of Gastrointestinal Recovery After Bowel Resection: Results of a Proof-of-Concept, Phase 2, Randomized, Double-Blinded, Placebo-Controlled Trial.Diseases of the colon and rectum · 2026Trial
- [A Randomized, Double-blind, Active-controlled Exploratory Clinical Trial for the Evaluation of the Efficacy and Safety of Goodmorning S GranuleThe Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi · 2022Trial
- Differential annotation of converted metabolites (DAC-Met): Exploration of Maoto (Ma-huang-tang)-derived metabolites in plasma using high-resolution mass spectrometry.Metabolomics : Official journal of the Metabolomic Society · 2020Trial
- The Acute and Chronic Cognitive and Cerebral Blood-Flow Effects of Nepalese Pepper (Nutrients · 2019Trial
- Daikenchuto and Processed Ginger Alleviate Liver Ischemia-Reperfusion Injury by Enhancing Anti-Inflammatory Effects and HO-1 Production.JGH open : an open access journal of gastroenterology and hepatology · 2026Article
- Daikenchuto ameliorates dextran sulfate sodium-induced acute and chronic ulcerative colitis by regulating gut microbiota-derived indoles to activate AhR signaling.Chinese medicine · 2026Article
- Keishikaryukotsuboreito Potentiates NGF-Induced Neurite Outgrowth in PC12 Cells.Life (Basel, Switzerland) · 2026Article
- Potential pharmacological quality control markers in the traditional Japanese medicine Hangeshashinto: identifying anti-inflammatory ingredients through a cell-based bioassay and multicomponent analysis.Pharmaceutical biology · 2025Article
- Role of the gut microbiota in the pharmacological effects of traditional Kampo medicine and natural products.Journal of natural medicines · 2025Review
- Pharmacotherapy for fecal incontinence: potential treatment with a traditional Japanese medicine Kampo.Annals of coloproctology · 2025Review
- The Antiviral Effect of Ephedrine Alkaloids-Free Ephedra Herb Extract, EFE, on Murine Coronavirus Growth in the Lung and Liver of Infected Mice.Microorganisms · 2025Article
- Development and Validation of an HPLC-PDA Method for Quality Control of Jwagwieum, an Herbal Medicine Prescription: Simultaneous Analysis of Nine Marker Compounds.Pharmaceuticals (Basel, Switzerland) · 2025Article
- Daikenchuto improves methotrexate-induced chronic small intestinal mucositis by promoting angiogenesis.Frontiers in pharmacology · 2025Article
- Stabilization of Hydroxy-α-Sanshool by Antioxidants Present in the GenusFoods (Basel, Switzerland) · 2023Article
- A Japanese Herbal Formula, Daikenchuto, Alleviates Experimental Colitis by Reshaping Microbial Profiles and Enhancing Group 3 Innate Lymphoid Cells.Frontiers in immunology · 2022Article
- Efficacy and Safety of the Japanese Herbal Medicine Daikenchuto (DKT) in Elderly Fecal Incontinence Patients: A Prospective Study.Journal of the anus, rectum and colon · 2022Article
- Identification of oxytocin receptor activating chemical components from traditional Japanese medicines.Journal of food and drug analysis · 2021Article
- Growth stimulation of Bifidobacterium from human colon using daikenchuto in an in vitro model of human intestinal microbiota.Scientific reports · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Herbal medicines have been used in Japan for more than 1500 years and traditional Japanese medicines (Kampo medicines) are now fully integrated into the modern healthcare system. In total, 148 Kampo formulae are officially approved as prescription drugs and covered by the national health insurance system in Japan. However, despite their long track record of clinical use, the multi-targeted, multi-component properties of Kampo medicines, which are fundamentally different from Western medicines, have made it difficult to create a suitable framework for conducting well-designed, large-scale clinical trials. In turn, this has led to misconceptions among western trained physicians concerning the paucity of scientific evidence for the beneficial effects of Kampo medicines. Fortunately, there has been a recent surge in scientifically robust data from basic and clinical studies for some of the Kampo medicines, e.g., daikenchuto (TU-100). Numerous basic and clinical studies on TU-100, including placebo-controlled double-blind studies for various gastrointestinal disorders, and absorption, distribution, metabolism and excretion (ADME) studies, have been conducted or are in the process of being conducted in both Japan and the USA. Clinical studies suggest that TU-100 is beneficial for postoperative complications, especially ileus and abdominal bloating. ADME and basic studies indicate that the effect of TU-100 is a composite of numerous actions mediated by multiple compounds supplied via multiple routes. In addition to known mechanisms of action via enteric/sensory nerve stimulation, novel mechanisms via the TRPA1 channel and two pore domain potassium channels have recently been elucidated. TU-100 compounds target these channels with and without absorption, both before and after metabolic activation by enteric flora, with different timings and possibly with synergism.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.